

Aaron R Hansen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3527322/publications.pdf>

Version: 2024-02-01

221
papers

13,840
citations

47006

47
h-index

23533

111
g-index

222
all docs

222
docs citations

222
times ranked

18447
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. <i>Lancet, The</i> , 2019, 394, 1915-1928.	13.7	1,804
2	Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 1-10.	1.6	1,740
3	Tumour heterogeneity in the clinic. <i>Nature</i> , 2013, 501, 355-364.	27.8	993
4	Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. <i>Annals of Oncology</i> , 2017, 28, 2377-2385.	1.2	631
5	Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. <i>Lancet Oncology, The</i> , 2016, 17, 440-451.	10.7	607
6	Deintensification Candidate Subgroups in Human Papillomavirus-Related Oropharyngeal Cancer According to Minimal Risk of Distant Metastasis. <i>Journal of Clinical Oncology</i> , 2013, 31, 543-550.	1.6	551
7	Overview of the 8th Edition TNM Classification for Head and Neck Cancer. <i>Current Treatment Options in Oncology</i> , 2017, 18, 40.	3.0	455
8	Refining American Joint Committee on Cancer/Union for International Cancer Control TNM Stage and Prognostic Groups for Human Papillomavirus-Related Oropharyngeal Carcinomas. <i>Journal of Clinical Oncology</i> , 2015, 33, 836-845.	1.6	345
9	Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 4050-4056.	1.6	335
10	Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. <i>International Journal of Cancer</i> , 2020, 147, 2190-2198.	5.1	288
11	Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. <i>Annals of Oncology</i> , 2018, 29, 1807-1813.	1.2	261
12	Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. <i>Oral Oncology</i> , 2013, 49, 79-85.	1.5	239
13	Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. <i>Genome Medicine</i> , 2016, 8, 109.	8.2	211
14	Atypical Clinical Behavior of p16-Confirmed HPV-Related Oropharyngeal Squamous Cell Carcinoma Treated With Radical Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 276-283.	0.8	207
15	Tracking the dynamics of circulating tumour cell phenotypes using nanoparticle-mediated magnetic ranking. <i>Nature Nanotechnology</i> , 2017, 12, 274-281.	31.5	198
16	Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 752-761.	1.6	189
17	A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. <i>Annals of Oncology</i> , 2015, 26, 1824-1829.	1.2	184
18	Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation. <i>Radiotherapy and Oncology</i> , 2012, 103, 49-56.	0.6	167

#	ARTICLE	IF	CITATIONS
19	PD-L1 Testing in Cancer. <i>JAMA Oncology</i> , 2016, 2, 15.	7.1	116
20	Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity. <i>Clinical Cancer Research</i> , 2017, 23, 4959-4969.	7.0	115
21	Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities. <i>Cancer</i> , 2019, 125, 1341-1349.	4.1	115
22	Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 1563-1574.	1.6	108
23	Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor. <i>Journal of Urology</i> , 2018, 200, 126-135.	0.4	107
24	Point-of-care outcome assessment in the cancer clinic: Audit of data quality. <i>Radiotherapy and Oncology</i> , 2010, 95, 339-343.	0.6	105
25	Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. <i>JAMA Network Open</i> , 2021, 4, e2021869.	5.9	104
26	Temporal Nodal Regression and Regional Control After Primary Radiation Therapy for N2-N3 Head-and-Neck Cancer Stratified by HPV Status. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 1078-1085.	0.8	100
27	Osteoradionecrosis of the mandible in patients with oropharyngeal carcinoma treated with intensity-modulated radiotherapy. <i>Cancer</i> , 2017, 123, 3691-3700.	4.1	99
28	Long-Term Late Toxicity, Quality of Life, and Emotional Distress in Patients With Nasopharyngeal Carcinoma Treated With Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 340-352.	0.8	99
29	Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 773-785.	4.2	94
30	Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors. <i>BioDrugs</i> , 2016, 30, 571-584.	4.6	93
31	The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky021.	2.9	92
32	The microbiome and cancer for clinicians. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 141, 1-12.	4.4	84
33	A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer. <i>Genetics in Medicine</i> , 2016, 18, 128-136.	2.4	83
34	A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. <i>British Journal of Cancer</i> , 2019, 120, 1113-1119.	6.4	83
35	Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 1553-1562.	1.6	83
36	Early phase clinical trials to identify optimal dosing and safety. <i>Molecular Oncology</i> , 2015, 9, 997-1007.	4.6	81

#	ARTICLE	IF	CITATIONS
37	Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2016, 67, 174-182.	2.8	75
38	First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. <i>European Urology</i> , 2019, 76, 861-867.	1.9	71
39	Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic review. <i>British Journal of Cancer</i> , 2017, 117, 1743-1752.	6.4	68
40	Re-evaluation of Ipsilateral Radiation for T1-T2N0-N2b Tonsil Carcinoma at the Princess Margaret Hospital in the Human Papillomavirus Era, 25 Years Later. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 159-169.	0.8	61
41	Phase 1 Trial Design: Is 3 + 3 the Best?. <i>Cancer Control</i> , 2014, 21, 200-208.	1.8	59
42	Radiomic Biomarkers to Refine Risk Models for Distant Metastasis in HPV-related Oropharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1107-1116.	0.8	57
43	Outcomes and prognostic factors for major salivary gland carcinoma following postoperative radiotherapy. <i>Oral Oncology</i> , 2016, 54, 75-80.	1.5	56
44	Patient-Derived Xenografts for Prognostication and Personalized Treatment for Head and Neck Squamous Cell Carcinoma. <i>Cell Reports</i> , 2018, 25, 1318-1331.e4.	6.4	56
45	A comprehensive review of immunotherapies in prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 292-303.	4.4	55
46	Conditional Risk of Relapse in Surveillance for Clinical Stage I Testicular Cancer. <i>European Urology</i> , 2017, 71, 120-127.	1.9	54
47	Radiologic Extranodal Extension Portends Worse Outcome in cN+ TNM-8 Stage I Human Papillomavirus-Mediated Oropharyngeal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 1017-1027.	0.8	50
48	Radiologic-Pathologic Correlation of Extranodal Extension in Patients With Squamous Cell Carcinoma of the Oral Cavity: Implications for Future Editions of the TNM Classification. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 698-708.	0.8	48
49	Comparison of Health State Utility Measures in Patients With Head and Neck Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2015, 141, 696.	2.2	47
50	Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance. <i>Journal of Clinical Oncology</i> , 2019, 37, 1919-1926.	1.6	47
51	A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma. <i>Oncotarget</i> , 2017, 8, 32918-32929.	1.8	46
52	The changing incidence of human papillomavirus-associated oropharyngeal cancer using multiple imputation from 2000 to 2010 at a Comprehensive Cancer Centre. <i>Cancer Epidemiology</i> , 2013, 37, 820-829.	1.9	42
53	Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal. <i>Cancer</i> , 2020, 126, 3426-3437.	4.1	42
54	Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI. <i>Oral Oncology</i> , 2020, 108, 104736.	1.5	40

#	ARTICLE	IF	CITATIONS
55	Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer. <i>European Urology Oncology</i> , 2021, 4, 483-491.	5.4	39
56	An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)., 2019, 7, 72.		38
57	Morphologic and topographic radiologic features of human papillomavirus-related and "unrelated oropharyngeal carcinoma. <i>Head and Neck</i> , 2017, 39, 1524-1534.	2.0	37
58	Structure and Optimization of Checkpoint Inhibitors. <i>Cancers</i> , 2020, 12, 38.	3.7	37
59	Epidermal Growth Factor Receptor Targeting in Head and Neck Cancer: Have We Been Just Skimming the Surface?. <i>Journal of Clinical Oncology</i> , 2013, 31, 1381-1383.	1.6	36
60	Assessment Criteria and Clinical Implications of Extranodal Extension in Head and Neck Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 265-278.	3.8	35
61	Challenges in establishing the diagnosis of human papillomavirus-related oropharyngeal carcinoma. <i>Laryngoscope</i> , 2016, 126, 2270-2275.	2.0	33
62	A Phase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , 2015, 21, 258-266.	7.0	32
63	Mitosis Trumps T Stage and Proposed International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification for Prognostic Value in Resected Stage 1 Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2015, 10, 673-681.	1.1	32
64	Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC). <i>Oncologist</i> , 2019, 24, 1188-1194.	3.7	32
65	Impact of p16 expression, nodal status, and smoking on oncologic outcomes of patients with head and neck unknown primary squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, 1347-1353.	2.0	31
66	Cost-Effectiveness Analysis of Radiation Therapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 709-717.	0.8	31
67	Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology Oncology</i> , 2019, 2, 643-648.	5.4	31
68	Prognostic importance of radiologic extranodal extension in HPV-positive oropharyngeal carcinoma and its potential role in refining TNM-8 cN-classification. <i>Radiotherapy and Oncology</i> , 2020, 144, 13-22.	0.6	30
69	Phenotypic Profiling of Circulating Tumor Cells in Metastatic Prostate Cancer Patients Using Nanoparticle-Mediated Ranking. <i>Analytical Chemistry</i> , 2019, 91, 9348-9355.	6.5	29
70	Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 858-867.	7.0	28
71	Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck. <i>Cancer Treatment Reviews</i> , 2017, 54, 43-57.	7.7	28
72	Effect of Intensity Modulated Radiation Therapy With Concurrent Chemotherapy on Survival for Patients With Cervical Esophageal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 186-195.	0.8	27

#	ARTICLE	IF	CITATIONS
73	Development of the Functional Assessment of Cancer Therapyâ€œImmune Checkpoint Modulator (FACTâ€œICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. <i>Cancer</i> , 2020, 126, 1550-1558.	4.1	26
74	Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021, 4, 102-111.	5.4	26
75	The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial. <i>European Journal of Cancer</i> , 2019, 108, 69-77.	2.8	25
76	Measuring financial toxicity incurred after treatment of head and neck cancer: Development and validation of the Financial Index of Toxicity questionnaire. <i>Cancer</i> , 2020, 126, 4042-4050.	4.1	25
77	Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2021, 113, 980-988.	6.3	25
78	Human papillomavirus and p16 immunostaining, prevalence and prognosis of squamous carcinoma of unknown primary in the head and neck region. <i>International Journal of Cancer</i> , 2019, 145, 1465-1474.	5.1	24
79	Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library. <i>Oncologist</i> , 2019, 24, e146-e148.	3.7	23
80	A Phase I Study of Dinaciclib in Combination With MKâ€œ2206 in Patients With Advanced Pancreatic Cancer. <i>Clinical and Translational Science</i> , 2020, 13, 1178-1188.	3.1	23
81	Primary surgery versus (chemo)radiotherapy in oropharyngeal cancer. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2015, 23, 139-147.	1.8	22
82	Cabozantinib real-world effectiveness in the firstâ€œthrough fourthâ€œline settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Cancer Medicine</i> , 2021, 10, 1212-1221.	2.8	22
83	Prognostic importance of radiologic extranodal extension in nasopharyngeal carcinoma treated in a Canadian cohort. <i>Radiotherapy and Oncology</i> , 2021, 165, 94-102.	0.6	22
84	Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials. <i>Oncologist</i> , 2015, 20, 653-659.	3.7	21
85	Applying Radiomics to Predict Pathology of Postchemotherapy Retroperitoneal Nodal Masses in Germ Cell Tumors. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-12.	2.1	21
86	Cancer patientsâ€™ experiences with immune checkpoint modulators: A qualitative study. <i>Cancer Medicine</i> , 2020, 9, 3015-3022.	2.8	21
87	Radiotherapy Characteristics and Outcomes for Head and Neck Carcinoma of Unknown Primary vs T1 Base-of-Tongue Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2016, 142, 1208.	2.2	20
88	Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. <i>Cancer Research</i> , 2018, 78, 5398-5407.	0.9	20
89	Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study. , 2021, 9, e003476.		20
90	Exploring the Impact of Human Papillomavirus Status, Comorbidity, Polypharmacy, and Treatment Intensity on Outcome of Elderly Oropharyngeal Cancer Patients Treated With Radiation Therapy With or Without Chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 858-867.	0.8	19

#	ARTICLE	IF	CITATIONS
91	Clinical application of high-throughput genomic technologies for treatment selection in breast cancer. <i>Breast Cancer Research</i> , 2013, 15, R97.	5.0	17
92	Hypopharyngeal Cancer: Looking Back, Moving Forward. <i>Current Oncology</i> , 2016, 23, 221-222.	2.2	17
93	Partial Laryngeal IMRT for T2NO Glottic Cancer: Impact of Image Guidance and Radiation Therapy Intensification. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 941-949.	0.8	17
94	Treatment implications of postoperative chemoradiotherapy for squamous cell carcinoma of the oral cavity with minor and major extranodal extension. <i>Oral Oncology</i> , 2020, 110, 104845.	1.5	17
95	Advanced Adrenocortical Carcinoma (ACC): a Review with Focus on Second-Line Therapies. <i>Hormones and Cancer</i> , 2020, 11, 155-169.	4.9	17
96	A comparison of weekly versus 3-weekly cisplatin during adjuvant radiotherapy for high-risk head and neck cancer. <i>Oral Oncology</i> , 2016, 59, 43-49.	1.5	16
97	The Current State of Biological and Clinical Implications of Human Papillomavirus-Related Oropharyngeal Cancer. <i>Seminars in Radiation Oncology</i> , 2018, 28, 17-26.	2.2	16
98	Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen-receptor-targeted therapy for metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2021, 127, 2587-2594.	4.1	16
99	Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS).. <i>Journal of Clinical Oncology</i> , 2013, 31, 11002-11002.	1.6	16
100	The interplay of IMRT and transoral surgery in HPV-mediated oropharyngeal cancer: Getting the balance right. <i>Oral Oncology</i> , 2018, 86, 171-180.	1.5	15
101	Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy. <i>European Journal of Cancer</i> , 2019, 118, 112-120.	2.8	14
102	Computer-assisted image analysis of the tumor microenvironment on an oral tongue squamous cell carcinoma tissue microarray. <i>Clinical and Translational Radiation Oncology</i> , 2019, 17, 32-39.	1.7	14
103	Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa115.	2.9	14
104	Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma. <i>European Journal of Cancer</i> , 2019, 123, 138-145.	2.8	13
105	Early circulating tumor DNA (ctDNA) kinetics using a tumor-naïve assay as a predictive biomarker in early-phase immunotherapy (IO) clinical trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2546-2546.	1.6	13
106	Recommendations for followup of stage I and II seminoma: The Princess Margaret Cancer Centre approach. <i>Canadian Urological Association Journal</i> , 2017, 12, 59-66.	0.6	12
107	Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group. <i>Oncologist</i> , 2020, 25, 422-430.	3.7	12
108	Postoperative wound infections, neutrophil-to-lymphocyte ratio, and cancer recurrence in patients with oral cavity cancer undergoing surgical resection. <i>Oral Oncology</i> , 2019, 97, 23-30.	1.5	11

#	ARTICLE	IF	CITATIONS
109	Detection of Relapse by Low-dose Computed Tomography During Surveillance in Stage I Testicular Germ Cell Tumours. <i>European Urology Oncology</i> , 2019, 2, 437-442.	5.4	11
110	Mapping the EORTC QLQ-C30 and QLQ-H&N35, onto EQ-5D and HUI-3 indices in patients with head and neck cancer. <i>Head and Neck</i> , 2020, 42, 2277-2286.		11
111	Prognostic value of clinical and radiologic extranodal extension and their role in the 8th edition TNM cN classification for HPV-negative oropharyngeal carcinoma. <i>Oral Oncology</i> , 2021, 114, 105167.	1.5	11
112	Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. <i>Canadian Urological Association Journal</i> , 2020, 15, 84-97.	0.6	11
113	Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Network Open</i> , 2021, 4, e2114694.	5.9	11
114	A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3K β/δ , in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 2257-2269.	7.0	11
115	Mapping the University of Washington Quality of life questionnaire onto EQ-5D and HUI-3 indices in patients with head and neck cancer. <i>Head and Neck</i> , 2020, 42, 513-521.	2.0	10
116	Health-related quality of life assessment of patients with solid tumors on immuno-oncology therapies. <i>Cancer</i> , 2021, 127, 1360-1368.	4.1	10
117	Out-of-pocket costs associated with head and neck cancer treatment. <i>Cancer Reports</i> , 2022, 5, e1528.	1.4	10
118	Clinical presentation and outcome of human papillomavirus-positive nasopharyngeal carcinoma in a North American cohort. <i>Cancer</i> , 2022, 128, 2908-2921.	4.1	10
119	Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001). <i>Investigational New Drugs</i> , 2016, 34, 575-583.	2.6	9
120	Determinants of the recommended phase 2 dose of molecular targeted agents. <i>Cancer</i> , 2017, 123, 1409-1415.	4.1	9
121	Systematic review and REMARK scoring of renal cell carcinoma prognostic circulating biomarker manuscripts. <i>PLoS ONE</i> , 2019, 14, e0222359.	2.5	9
122	Biomarkers in Non-Schistosomiasis-related squamous cell carcinoma of the urinary bladder: A review. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 135, 76-84.	4.4	9
123	Pre- and Post-Radiotherapy Radiologic Nodal Features and Oropharyngeal Cancer Outcomes. <i>Laryngoscope</i> , 2021, 131, E1162-E1171.	2.0	9
124	A phase II study of suberoylanilide hydroxamic acid (SAHA) in subjects with locally advanced, recurrent, or metastatic adenoid cystic carcinoma (ACC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 6045-6045.	1.6	9
125	Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 642-642.	1.6	9
126	Single institution retrospective review of perioperative chemotherapy in adult and adolescent patients with operable osteosarcoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, e222-e228.	1.1	8

#	ARTICLE	IF	CITATIONS
127	Gene expression signatures prognostic for relapse in stage I testicular germ cell tumours. <i>BJU International</i> , 2018, 122, 814-822.	2.5	8
128	Multiple imputation and clinico-serological models to predict human papillomavirus status in oropharyngeal carcinoma: An alternative when tissue is unavailable. <i>International Journal of Cancer</i> , 2020, 146, 2166-2174.	5.1	8
129	Impact of cumulative cisplatin dose and adjuvant chemotherapy in locally-advanced nasopharyngeal carcinoma treated with definitive chemoradiotherapy. <i>Oral Oncology</i> , 2020, 105, 104666.	1.5	8
130	Principles of cancer staging. , 0, , 34-39.		8
131	Treatment outcomes and survival following definitive (chemo)radiotherapy in HPV-positive oropharynx cancer: Large-scale comparison of DAHANCA vs PMH cohorts. <i>International Journal of Cancer</i> , 2022, 150, 1329-1340.	5.1	8
132	Finding/identifying primaries with neck disease (FIND) clinical trial protocol: a study integrating transoral robotic surgery, histopathological localisation and tailored deintensification of radiotherapy for unknown primary and small oropharyngeal head and neck squamous cell carcinoma. <i>BMJ Open</i> , 2019, 9, e035431.	1.9	7
133	Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift?. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1753-1768.	2.4	7
134	Alpha Test of Intelligent Machine Learning in Staging Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1255-1257.	1.6	7
135	Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223. <i>Cancer Medicine</i> , 2021, 10, 5775-5782.	2.8	7
136	A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 3032-3041.	7.0	7
137	First in human study with GSK3359609 [GSK609], inducible T cell co-stimulator (ICOS) receptor agonist in patients [Pts] with advanced, solid tumors: Preliminary results from INDUCE-1. <i>Annals of Oncology</i> , 2018, 29, viii404.	1.2	6
138	First-in-class microbial ecosystem therapeutics 4 (MET4) in metastatic solid cancer patients treated with immunotherapy: MET4-IO.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3098-3098.	1.6	6
139	Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry. <i>F1000Research</i> , 2020, 9, 337.	1.6	6
140	HPV Status Improves Classification of Head and Neck Gray Zone Cancers. <i>Journal of Dental Research</i> , 2019, 98, 879-887.	5.2	5
141	Pathologic concordance of resected metastatic nonseminomatous germ cell tumors in the chest. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 161, 856-868.e1.	0.8	5
142	Recurrent Myocarditis Induced by Immune-Checkpoint Inhibitor Treatment Is Accompanied by Persistent Inflammatory Markers Despite Immunosuppressive Treatment. <i>JCO Precision Oncology</i> , 2021, 5, 485-491.	3.0	5
143	Randomized phase Ib study to evaluate safety, pharmacokinetics and therapeutic activity of simlukafusp ± in combination with atezolizumab ± bevacizumab in patients with unresectable advanced/metastatic renal cell carcinoma (RCC) (NCT03063762).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4556-4556.	1.6	5
144	Quality of patient-reported outcomes in oncology clinical trials using immune checkpoint inhibitors: A systematic review. <i>Cancer Medicine</i> , 2021, 10, 5031-5040.	2.8	5

#	ARTICLE	IF	CITATIONS
145	Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 354-361.	1.9	5
146	Role of the oral and gut microbiota as a biomarker in locoregionally advanced oropharyngeal squamous cell carcinoma (ROMA LA-OPSCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 6045-6045.	1.6	5
147	Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5063-5063.	1.6	5
148	Second-line VEGF TKI after IO combination therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 684-684.	1.6	5
149	Inter-rater concordance and operating definitions of radiologic nodal feature assessment in human papillomavirus-positive oropharyngeal carcinoma. <i>Oral Oncology</i> , 2022, 125, 105716.	1.5	5
150	Augmenting inter-rater concordance of radiologic extranodal extension in HPV-positive oropharyngeal carcinoma: A multicenter study. <i>Head and Neck</i> , 2022, 44, 2361-2369.	2.0	5
151	Surgery- vs Radiation-Based Therapy for p16+/HPV-Related Oropharyngeal Cancers. <i>Current Otorhinolaryngology Reports</i> , 2018, 6, 298-309.	0.5	4
152	Optimal Management of High-risk Stage I Nonseminomatous Germ Cell Tumor: Surveillance is the Preferred Option. <i>European Urology Focus</i> , 2019, 5, 702-703.	3.1	4
153	Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz071.	2.9	4
154	Controversies in the management of clinical stage 1 testis cancer. <i>Canadian Urological Association Journal</i> , 2020, 14, E537-E542.	0.6	4
155	Head and neck imaging surveillance strategy for HPV-positive oropharyngeal carcinoma following definitive (chemo)radiotherapy. <i>Radiotherapy and Oncology</i> , 2021, 157, 255-262.	0.6	4
156	Longitudinal health utility and symptom-toxicity trajectories in patients with head and neck cancers. <i>Cancer</i> , 2022, 128, 497-508.	4.1	4
157	Genomic characterization of non-schistosomiasis-related squamous cell carcinoma of the urinary bladder: A retrospective exploratory study. <i>PLoS ONE</i> , 2021, 16, e0259272.	2.5	4
158	Unfinished Business in Classifying HPV-Positive Oropharyngeal Carcinoma: Identifying the Bad Apples in a Good Staging Barrel. <i>Oncologist</i> , 2022, 27, 4-6.	3.7	4
159	Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 210-218.	1.9	4
160	Semen and serum platinum levels in cisplatin-treated survivors of germ cell cancer. <i>Cancer Medicine</i> , 2022, 11, 728-734.	2.8	4
161	Clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin inhibitors (mTORI) after immuno-oncology (IO) checkpoint inhibitors. <i>Annals of Oncology</i> , 2018, 29, viii315.	1.2	3
162	Phase I study of BI 754111 (anti-LAG-3) plus BI 754091(anti-PD-1) in patients (pts) with advanced solid cancers, followed by expansion in pts with microsatellite stable metastatic colorectal cancer (mCRC), anti-PD-(L)1-pretreated non-small cell lung cancer (NSCLC) and other solid tumors. <i>Annals of Oncology</i> , 2018, 29, viii441.	1.2	3

#	ARTICLE	IF	CITATIONS
163	Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e350-e359.	1.9	3
164	Dual Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancer: Just a Gambit or Real CheckMate?. <i>Cancer Cell</i> , 2020, 38, 438-440.	16.8	3
165	Systematic Review and STARD Scoring of Renal Cell Carcinoma Circulating Diagnostic Biomarker Manuscripts. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa050.	2.9	3
166	Simultaneous Vs Sequential Retroperitoneal, Thoracic and Cervical Resection of Post Chemotherapy Residual Masses in Patients With Metastatic Nonseminomatous Germ Cell Tumors of the Testis. <i>Urology</i> , 2020, 138, 69-76.	1.0	3
167	Use of combined androgen deprivation therapy with postoperative radiation treatment for prostate cancer: Impact of randomized trials on clinical practice. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 848.e1-848.e7.	1.6	3
168	Real-World Experience of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis). <i>Kidney Cancer</i> , 2021, 5, 21-29.	0.4	3
169	Molecular profiling and targeted agents in recurrent, metastatic salivary gland tumor (R/M SGT) patients (pts) treated at two academic centers.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6081-6081.	1.6	3
170	Development of a Functional Assessment of Chronic Illness Therapy item library and primary symptom list for the assessment of patient-reported adverse events associated with immune checkpoint modulators. <i>Journal of Cancer Metastasis and Treatment</i> , 2020, 2020, .	0.8	3
171	Barriers and facilitators to implementation of serial point-of-care hearing tests using a novel iPad-based audiometry in platinum chemotherapy-treated cancer patients (pts).. <i>Journal of Clinical Oncology</i> , 2020, 38, 223-223.	1.6	3
172	Randomized phase II trial of neoadjuvant abiraterone plus or minus cabazitaxel in high-risk prostate cancer: ACDC-RP.. <i>Journal of Clinical Oncology</i> , 2022, 40, 224-224.	1.6	3
173	Radiologicâ€“pathologic correlation of major versus minor extranodal extension in oral cavity cancer. <i>Head and Neck</i> , 2022, 44, 1422-1429.	2.0	3
174	A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study. <i>Targeted Oncology</i> , 2022, 17, 271-281.	3.6	3
175	Customized autoantibodies (autoAbs) profiling to predict and monitor immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors (ICI).. <i>Journal of Clinical Oncology</i> , 2022, 40, 2528-2528.	1.6	3
176	Treatment outcomes in oropharynx cancer patients who did not complete planned curative radiotherapy. <i>Oral Oncology</i> , 2019, 97, 124-130.	1.5	2
177	Significantly Minimizing Drug Wastage and the Cost of Cabazitaxel Used to Treat Metastatic Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2021, 79, 177-179.	1.9	2
178	Preliminary results of BEAVER: An investigator-initiated phase II study of binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts).. <i>Journal of Clinical Oncology</i> , 2021, 39, e15038-e15038.	1.6	2
179	Construct Validity of the EuroQoLâ€“5 Dimension and the Health Utilities Index in Head and Neck Cancer. <i>Otolaryngology - Head and Neck Surgery</i> , 2021, , 019459982110301.	1.9	2
180	Characterizing sites of metastatic involvement in metastatic clear-cell, papillary, and chromophobe renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5071-5071.	1.6	2

#	ARTICLE	IF	CITATIONS
181	Mapping PRO-CTCAE responses to clinician-graded adverse events, dose reductions, interruptions, and discontinuations in phase I cancer trials.. Journal of Clinical Oncology, 2020, 38, 2014-2014.	1.6	2
182	Methylated circulating tumor DNA (cfMeDIP) as a predictive biomarker of clinical outcome in pan-cancer patients (pts) treated with pembrolizumab (P).. Journal of Clinical Oncology, 2022, 40, 2550-2550.	1.6	2
183	The effect of circadian rhythm on clinical outcome in patients receiving pembrolizumab in the INSPIRE pan-cancer trial.. Journal of Clinical Oncology, 2022, 40, 2589-2589.	1.6	2
184	Transoral robotic surgery (TORS)-guided radiotherapy (RT) volume de-intensification in p16-positive unknown primary squamous cell carcinoma (SCC) of the neck: A phase 2 trial (FIND).. Journal of Clinical Oncology, 2022, 40, 6067-6067.	1.6	2
185	Reply to J.J. Beitler et al. Journal of Clinical Oncology, 2015, 33, 3218-3219.	1.6	1
186	Shrinking Hepatic Hemangiomas in a Patient Treated for Metastatic Germ Cell Tumor. Clinical Genitourinary Cancer, 2018, 16, e69-e72.	1.9	1
187	Referrals to a Phase I Clinic and Trial Enrollment in the Molecular Screening Era. Oncologist, 2019, 24, e518-e525.	3.7	1
188	Durable therapeutic gain despite competing mortality in long-term follow-up of a randomized hyperfractionated radiotherapy trial for locally advanced head and neck cancer. Clinical and Translational Radiation Oncology, 2020, 21, 69-76.	1.7	1
189	A systematic review of immune-related adverse event (irAE) reporting in clinical trials of immune checkpoint inhibitors (ICIs).. Journal of Clinical Oncology, 2014, 32, 3057-3057.	1.6	1
190	Recurrent or metastatic salivary gland tumor (MSGT) patients treated with selinexor, a first in class selective exportin-1 (XPO1) inhibitor.. Journal of Clinical Oncology, 2020, 38, 6586-6586.	1.6	1
191	A New Staging System for HPV-Related Oropharynx Cancer: Rationale, Derivation, Validation and Practical Applications. , 2018, , 149-164.		1
192	An evaluation of administrative data linkage for measurement of real-world outcomes of large clinical panel sequencing for advanced solid tumors.. Journal of Clinical Oncology, 2020, 38, 283-283.	1.6	1
193	Association of cabozantinib dose reductions for toxicity with clinical effectiveness in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).. Journal of Clinical Oncology, 2022, 40, 316-316.	1.6	1
194	Daily symptom monitoring commonly leads to treatment modification in older adults receiving treatment for metastatic prostate cancer (mPC).. Journal of Clinical Oncology, 2022, 40, 82-82.	1.6	1
195	An Exploratory Study of Refining TNM-8 M1 Categories and Prognostic Subgroups Using Plasma EBV DNA for Previously Untreated De Novo Metastatic Nasopharyngeal Carcinoma. Cancers, 2022, 14, 1923.	3.7	1
196	External validation of the VIGex gene-expression signature (GES) as a novel predictive biomarker for immune checkpoint treatment (ICT).. Journal of Clinical Oncology, 2022, 40, 2510-2510.	1.6	1
197	Predicting toxicity and response to pembrolizumab (P) through germline genomic HLA class I analysis. Annals of Oncology, 2018, 29, viii29.	1.2	0
198	Phase II study of CC-486 in previously treated patients (pts) with locally advanced/metastatic nasopharyngeal cancer (NPC): Final results. Annals of Oncology, 2018, 29, viii382.	1.2	0

#	ARTICLE	IF	CITATIONS
199	Minimally Invasive Real-Time Detection of Actionable Mutations in Patients With Metastatic Solid Tumors Using Fine-Needle and Liquid Biopsies. <i>JCO Precision Oncology</i> , 2018, 2, 1-20.	3.0	0
200	Predictive radiomics signature for treatment response to nivolumab in patients (pts) with advanced renal cell carcinoma (RCC). <i>Annals of Oncology</i> , 2018, 29, viii318.	1.2	0
201	Characterization and outcomes of patients enrolled to multiple phase I cancer trials. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 469-472.	2.3	0
202	Contemporary Opportunities in Nonsurgical Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma. , 2021, , 119-137.		0
203	Phase I Study Methodology in Head and Neck Oncology. , 2016, , 731-742.		0
204	Treatment of Viral-Associated HNC (OPC and NPC). , 2017, , 177-188.		0
205	Human Papillomavirus and Head and Neck Cancer. , 2018, , 167-181.		0
206	An evaluation of administrative data linkage for measurement of real-world outcomes of large clinical panel sequencing for advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, e19303-e19303.	1.6	0
207	Persistence of platinum in semen of cisplatin-treated survivors of advanced testicular cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5056-5056.	1.6	0
208	Salvage chemotherapy for metastatic germ cell tumours: The known unknowns. <i>Canadian Urological Association Journal</i> , 2012, 6, 117-8.	0.6	0
209	Risk Stratification of HPV-Associated Oropharyngeal Squamous Cell Carcinoma: Are All Tumors Created Equally?. <i>Current Otorhinolaryngology Reports</i> , 2022, 10, 68.	0.5	0
210	Comparison of patients with high-risk nonmetastatic clear cell renal carcinoma in adjuvant therapy trials versus nonclinical trial patients.. <i>Journal of Clinical Oncology</i> , 2022, 40, 361-361.	1.6	0
211	The survival outcomes of the metastatic renal cell carcinoma with rhabdoid differentiation in immunotherapy era: Princess Margaret Cancer Center experience.. <i>Journal of Clinical Oncology</i> , 2022, 40, 333-333.	1.6	0
212	Efficacy of tyrosine kinase inhibitors (TKI) after combination ipilimumab plus nivolumab (I/N) in metastatic clear cell renal cell carcinoma (ccmRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCs).. <i>Journal of Clinical Oncology</i> , 2022, 40, 346-346.	1.6	0
213	Effectiveness of first-line therapy in patients with advanced non-clear renal cell carcinoma (nccRCC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 304-304.	1.6	0
214	Genomic characterization and identification of actionable variants in patients with locally advanced or metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 562-562.	1.6	0
215	The role of cytoreductive nephrectomy and systemic therapy in the management of tumor thrombus in patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 345-345.	1.6	0
216	Survival outcomes of metastatic renal cell carcinoma (mRCC) with sarcomatoid differentiation (SD): A single-institutional experience and literature meta-analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 332-332.	1.6	0

#	ARTICLE	IF	CITATIONS
217	Case of Intra-abdominal metastases following ventriculoperitoneal shunt insertion for primary intracranial germ cell tumor. Canadian Urological Association Journal, 2022, 16, .	0.6	0
218	A randomized study to measure and enhance the health-related quality of life in patients with cancer receiving immune checkpoint modulators (ME-Q).. Journal of Clinical Oncology, 2022, 40, TPS6603-TPS6603.	1.6	0
219	Randomized controlled trial (RCT) of symptom screening with targeted early palliative care (STEP) versus usual care in patients with advanced cancer.. Journal of Clinical Oncology, 2022, 40, e24084-e24084.	1.6	0
220	Remote symptom monitoring (RSM) during treatment for metastatic prostate cancer (mPC) in older men: Feasibility and efficacy.. Journal of Clinical Oncology, 2022, 40, 12056-12056.	1.6	0
221	Is there a role for surgery after chemotherapy in recurrent/metastatic adrenal cortical cancer (ACC)?. Journal of Clinical Oncology, 2022, 40, 5092-5092.	1.6	0